HAP Trading’s Accelerate Diagnostics AXDX Stock Holding History

HAP Trading’s Portfolio AXDX Stock Details AXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-1,177	Closed	-$270K	–	1124
2018 Q3	$270K	Buy	+1,177	New	+$260K	0.02%	400

Other funds holding AXDX

GAM

Griffin Asset Management New York $887M AUM 21.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

HAP Trading's AXDX Position: Q4 2018 in Review

HAP Trading sold out of Accelerate Diagnostics (AXDX) in Q4 2018, closing a stake of 1,177 shares — an estimated $270K sold.

HAP Trading first reported a position in AXDX in Q3 2018 and held it in 1 quarter. The position peaked at $270K in Q3 2018. 107 funds tracked by Wall St. Rank hold AXDX as of Q4 2018.

HAP Trading reported no remaining Accelerate Diagnostics position as of Q4 2018 after selling out during the quarter.
HAP Trading sold 1,177 Accelerate Diagnostics shares in Q4 2018, an estimated $270K.
HAP Trading first reported a position in Accelerate Diagnostics in Q3 2018 and held it in 1 quarter.
HAP Trading's Accelerate Diagnostics position peaked at $270K in Q3 2018.
107 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q4 2018.

Based on HAP Trading's 13F filing for Q4 2018, filed 12 Feb 2019.